---
figid: PMC8261392__41576_2021_383_Fig5_HTML
figtitle: Theranostic cells for non-cancer applications
organisms:
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella enterica subsp. enterica serovar Typhimurium
- Vibrio cholerae
- Mycobacterium tuberculosis variant bovis BCG
- Mycobacterium tuberculosis variant bovis
- Bifidobacterium longum
- Escherichia coli Nissle 1917
- Human immunodeficiency virus 1
- Severe acute respiratory syndrome coronavirus 2
- Adenoviridae
- Adeno-associated virus
- Zika virus
- Ebola virus
- Mus musculus
- Rattus norvegicus
- gut metagenome
- human metagenome
- Homo sapiens
- Saccharomyces cerevisiae
- Sus scrofa
- synthetic gene
organisms_ner:
- Rattus norvegicus
- Sus scrofa
- Mus musculus
- Homo sapiens
pmcid: PMC8261392
filename: 41576_2021_383_Fig5_HTML.jpg
figlink: /pmc/articles/PMC8261392/figure/Fig5/
number: F5
caption: a | Cytokine converter cells sense the presence of two inflammatory cytokines
  expressed in psoriasis, TNF and IL-22, and express anti-inflammatory cytokines,
  IL-4 and IL-10, in response. The endogenous TNF receptor (TNFR)/NF-κB signalling
  pathway of HEK293 cells is rewired to activate expression of IL-22 receptor-α (IL-22RA)
  in the presence of TNF. When IL-22RA is expressed and IL-22 is present, IL-22RA
  and endogenous IL-10RB dimerize and activate the endogenous JAK–STAT pathway. STAT3
  signalling is rewired to activate expression of anti-inflammatory cytokines IL-4
  and IL-10 that can improve the psoriatic phenotype by calming inflammation. b |
  Highlighted strategies for engineering native therapeutic pathways in mesenchymal
  stem cells include expression of receptor intracellular domains to induce a pro-erythropoietic
  phenotype (step 1), transgenic expression of vascular endothelial growth factor
  (VEGF) (step 2) and upregulation of the native isoforms of VEGF to promote angiogenesis
  (step 3).
papertitle: 'Theranostic cells: emerging clinical applications of synthetic biology.'
reftext: Monica P. McNerney, et al. Nat Rev Genet. 2021;22(11):730-746.
year: '2021'
doi: 10.1038/s41576-021-00383-3
journal_title: Nature Reviews. Genetics
journal_nlm_ta: Nat Rev Genet
publisher_name: Nature Publishing Group UK
keywords: Biotechnology | Therapeutics
automl_pathway: 0.9529321
figid_alias: PMC8261392__F5
figtype: Figure
redirect_from: /figures/PMC8261392__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8261392__41576_2021_383_Fig5_HTML.html
  '@type': Dataset
  description: a | Cytokine converter cells sense the presence of two inflammatory
    cytokines expressed in psoriasis, TNF and IL-22, and express anti-inflammatory
    cytokines, IL-4 and IL-10, in response. The endogenous TNF receptor (TNFR)/NF-κB
    signalling pathway of HEK293 cells is rewired to activate expression of IL-22
    receptor-α (IL-22RA) in the presence of TNF. When IL-22RA is expressed and IL-22
    is present, IL-22RA and endogenous IL-10RB dimerize and activate the endogenous
    JAK–STAT pathway. STAT3 signalling is rewired to activate expression of anti-inflammatory
    cytokines IL-4 and IL-10 that can improve the psoriatic phenotype by calming inflammation.
    b | Highlighted strategies for engineering native therapeutic pathways in mesenchymal
    stem cells include expression of receptor intracellular domains to induce a pro-erythropoietic
    phenotype (step 1), transgenic expression of vascular endothelial growth factor
    (VEGF) (step 2) and upregulation of the native isoforms of VEGF to promote angiogenesis
    (step 3).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tnf
  - Nfkb1
  - Il22
  - Il10rb
  - Stat3
  - Il4
  - Il10
  - Vegfa
  - TNF
  - IL22
  - IL10RB
  - STAT3
  - IL4
  - IL4R
  - IL10
  - VEGFA
  - Tnfrsf1a
  - TNFRSF1A
  - NFKB1
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
---
